TRPC6 and cancer: In summary, we demonstrated that Trpc6 deficiency alone is sufficient to protect male mice from doxorubicin-induced cardiac damage and decline in cardiac function, suggesting that TRPC6 may be a valuable therapeutic target for cancer patients who require doxorubicin.